Browse the evidence

Metformin decreased the risk of diabetes among individuals with prediabetes by 3.2 cases per 100 person-years during 3 years.

Metformin can be an effective option for certain individuals at risk of diabetes.

Obesity contributes to poor health outcomes, reduced quality of life, and over 2.8 million deaths each year.

Healthcare providers should prioritize obesity management to improve health outcomes.

People living with overweight/obesity are at greater risk for cardiovascular morbidity and mortality.

Clinicians should assess cardiovascular risk in patients with obesity.

GLP-1 RA use is associated with increased risk of gallbladder or biliary diseases for longer durations (RR, 1.40; 95% CI, 1.26-1.56) compared to shorter durations (RR, 0.79; 95% CI, 0.48-1.31).

Clinicians should monitor patients on GLP-1 RAs for gallbladder issues, especially with prolonged use.

Obesity has been declared a disease that results in impaired quality of life and reduced life expectancy.

Healthcare practitioners should recognize obesity as a disease and address its impact on patients' quality of life.

Two-thirds of obesity-related excess mortality is attributable to cardiovascular disease.

Efforts to reduce obesity should be prioritized to decrease cardiovascular disease mortality.

Obesity is underrecognized and sub-optimally addressed compared to other modifiable cardiovascular risk factors.

Clinicians should enhance their focus on obesity as a critical cardiovascular risk factor.

At 7 years, HbA1c decreased by 1.6% in the bariatric surgery group compared to a decrease of 0.2% in the medical/lifestyle management group.

Bariatric surgery may lead to significantly better long-term glycemic control compared to medical management.

Diabetes remission rates were higher in the bariatric surgery group, with 18.2% achieving remission at 7 years compared to 6.2% in the medical/lifestyle group.

Bariatric surgery may significantly increase the likelihood of diabetes remission compared to medical management.

1-year reinitiation was lower for those without type 2 diabetes (36.3%) compared with those with type 2 diabetes (47.3%).

Practitioners should note that patients without type 2 diabetes may have lower rates of reinitiating GLP-1 RA therapy.

Certain subgroups of UPF, such as refined breads and sugar-sweetened beverages, are associated with higher T2D risk.

Focus on limiting intake of specific UPF subgroups to mitigate T2D risk.

High-quality meta-evidence supports the association between total UPF consumption and higher T2D risk.

Practitioners should consider the quality of evidence when advising on dietary choices related to UPF.

Common variables in definitions of sarcopenia include appendicular lean soft tissue mass, grip strength, and gait speed.

Understanding these variables can help practitioners assess sarcopenia more effectively.

Weight loss achieved through GLP-1–based antiobesity medications affects weight regain, fat-free mass, and skeletal muscle mass in people with obesity.

Practitioners should consider the impact of GLP-1 medications on body composition when managing obesity.

Wegovy rose from 989 in 2021 to 2992 in 2022.

The increase in Wegovy usage suggests a rising interest in GLP-1 receptor agonists for weight loss.

The monthly growth rates were 83.9% for Ozempic and 119.2% for Wegovy.

High monthly growth rates indicate a significant trend towards the use of GLP-1 receptor agonists for weight loss.

Liraglutide, 3.0 mg, is safe with no serious adverse events or treatment-related deaths reported.

Liraglutide can be considered a safe option for weight management in the studied population.

Food insecurity is a common cause of inadequate dietary intake.

Addressing food insecurity is crucial for improving dietary intake.

Higher sitting time (≥8 hours per day) is associated with an increased risk of all-cause mortality (HR, 1.20; 95% CI, 1.10-1.31) and major cardiovascular disease (HR, 1.21; 95% CI, 1.10-1.34).

Reducing sitting time to less than 8 hours per day may lower the risk of mortality and cardiovascular events.

The association of sitting time with the composite outcome is stronger in low-income and lower-middle-income countries (HR, 1.29; 95% CI, 1.16-1.44) compared to high-income and upper-middle-income countries (HR, 1.08; 95% CI, 0.98-1.19).

Public health strategies should focus on reducing sitting time, especially in low-income countries.

Participants who sat for 8 or more hours per day experienced a 17% to 50% higher associated risk of the composite outcome across physical activity levels.

Encouraging reduced sitting time is crucial, even for those who are physically active.

Bariatric surgery and GLP-1 receptor agonists have similar effects on glycemic control.

Both treatment options can be considered for glycemic control in obese patients.

Tirzepatide treatment was associated with lower hazards of all-cause mortality compared to GLP-1 RA (adjusted hazard ratio [AHR], 0.58; 95% CI, 0.45-0.75).

Practitioners may consider tirzepatide as a safer option for reducing mortality risk in patients with type 2 diabetes.

Tirzepatide treatment was associated with lower hazards of major adverse cardiovascular events (MACEs) compared to GLP-1 RA (AHR, 0.80; 95% CI, 0.71-0.91).

Tirzepatide may be a preferable treatment option for reducing cardiovascular risks in patients with type 2 diabetes.